EGFR and non-small cell lung carcinoma: In the present study, we aimed to determine survival outcome in treatment-naïve NSCLC patients whose tumors harbored EGFR mutations and who were treated with EGFR TKIs as first-line therapy, with a focus on comparing non-responders to responders.